^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Systematic analysis of RNASET2 gene as a potential prognostic and immunological biomarker in clear cell renal cell carcinoma

Published date:
09/07/2023
Excerpt:
Similarly, high expression of RNASET2 in some targeted therapeutic agents increases the sensitivity of patients to the drug, such as vinblastine, linifanib, midostaurin, and vorinostat (Fig. 7, H to K).
DOI:
https://doi.org/10.1186/s12885-023-11356-6